Predicting MCI outcome with clinically available MRI and CSF biomarkers

D. Heister, J.B. Brewer, S. Magda, et al.

Neurology; Published online before print October 12, 2011;
DOI 10.1212/WNL.0b013e3182343314

Published Ahead of Print on October 12, 2011 as 10.1212/WNL.0b013e3182343314

Predicting MCI outcome with clinically available MRI and CSF biomarkers

D. Heister, MD, PhD
J.B. Brewer, MD, PhD
S. Magda, PhD
K. Blennow, MD, PhD
L.K. McEvoy, PhD
For the Alzheimer's Disease Neuroimaging Initiative

Address correspondence and reprint requests to Dr. Linda K. McEvoy, Department of Radiology, Mailcode 0841, School of Medicine, UCSD, 9500 Gilman Dr., La Jolla, CA 92093-0841; lkmcevoy@ucsd.edu

ABSTRACT

Objective: To determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer disease (AD) in patients with mild cognitive impairment (MCI).

Methods: We stratified 192 MCI participants into positive and negative risk groups on the basis of 1) degree of learning impairment on the Rey Auditory Verbal Learning Test; 2) medial temporal atrophy, quantified from Food and Drug Administration–approved software for automated vMRI analysis; and 3) CSF biomarker levels. We also stratified participants based on combinations of risk factors. We computed Cox proportional hazards models, controlling for age, to assess 3-year risk of converting to AD as a function of risk group and used Kaplan-Meier analyses to determine median survival times.

Results: When risk factors were examined separately, individuals testing positive showed significantly higher risk of converting to AD than individuals testing negative (hazard ratios [HR] 1.8–4.1). The joint presence of any 2 risk factors substantially increased risk, with the combination of greater learning impairment and increased atrophy associated with highest risk (HR 29.0): 85% of patients with both risk factors converted to AD within 3 years, vs 5% of those with neither. The presence of medial temporal atrophy was associated with shortest median dementia-free survival (15 months).

Conclusions: Incorporating quantitative assessment of learning ability along with vMRI or CSF biomarkers in the clinical workup of MCI can provide critical information on risk of imminent conversion to AD. *Neurology*® 2011;77:1619–1628

GLOSSARY

AD = Alzheimer disease; **ADNI** = Alzheimer's Disease Neuroimaging Initiative; **AVLT** = Auditory Rey Verbal Learning Test; **CDR** = Clinical Dementia Rating; **FDA** = Food and Drug Administration; **HC** = healthy control; **HOC** = hippocampal occupancy; **HR** = hazard ratio; **ILV** = inferior lateral ventricle; **MCI** = mild cognitive impairment; **MMSE** = Mini-Mental State Examination; **NINCDS-ADRDA** = National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association; **vMRI** = volumetric MRI.

Amnestic mild cognitive impairment (MCI) is associated with an increased but variable rate of progression to Alzheimer disease (AD). Severity of cognitive impairment, abnormal CSF biomarker levels, and atrophy on volumetric MRI (vMRI) each predict conversion to AD.[1–8] Combinations of these measures improve outcome prediction.[1,5,7,9–12]

Neuropsychological assessment is often used to diagnose MCI[13] but CSF and vMRI measures are not included in routine clinical workup of patients with MCI. These measures may be used to rule out other causes of dementia, such as cerebral infections and inflammatory disorders in the case of CSF,[14,15] or subdural hematoma and cerebrovascular pathology in the case of MRI,[16] but neither measure is currently used to support a diagnosis of early AD.

Methodologic barriers have prevented implementation of vMRI in clinical practice[17]; however, large-scale studies, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) and

Supplemental data at www.neurology.org

Supplemental Data

From the Departments of Radiology (D.H., J.B.B., L.K.M.) and Neurosciences (J.B.B.), University of California, San Diego, La Jolla; CorTechs Labs, Inc. (S.M.), La Jolla, CA; and Clinical Neurochemistry Laboratory (K.B.), Department of Neuroscience and Physiology, Sahlgrenska Academy, Göteborg University, Mölndal, Sweden.

Study funding: Funding information is provided at the end of the article.

Disclosure: Author disclosures are provided at the end of the article.

Table 1 Clinical and demographic data of patients with MCI who converted to AD over the 3-year follow-up and those who remained stable

	Stable (n = 108)	Converted (n = 84)	Statistical comparison
Male, n (%)	76 (70)	51 (61)	$\chi^2 = 1.97, p = 0.16$
Age, y	74.4 ± 0.71	74.9 ± 0.81	$F_{1,190} = 0.17; p = 0.68$
Education, y	16.0 ± 0.29	15.5 ± 0.33	$F_{1,190} = 1.19; p = 0.28$
APOE ε4 positive, n (%)	59 (45)	55 (65)	$\chi^2 = 7.69, p = 0.006$
MMSE	27.1 ± 0.17	26.6 ± 0.19	$F_{1,187} = 4.11; p = 0.044$
CDR-SB	1.4 ± 0.09	1.8 ± 0.10	$F_{1,187} = 8.84; p = 0.003$
ADAS-Cog	10.6 ± 0.42	13.0 ± 0.47	$F_{1,187} = 14.74; p < 0.001$
AVLT-Sum	33.0 ± 0.76	26.9 ± 0.86	$F_{1,187} = 27.75; p < 0.001$
HC/ICV	0.49 ± 0.006	0.45 ± 0.007	$F_{1,188} = 16.04; p < 0.001$
HOC	0.70 ± 0.009	0.63 ± 0.010	$F_{1,188} = 19.49; p < 0.001$
CSF $A\beta_{142}$, pg/mL	177.0 ± 5.02	145. 5 ± 6.70	$F_{1,190} = 17.21; p < 0.001$
CSF T-tau, pg/mL	95.9 ± 5.85	114.0 ± 6.63	$F_{1,190} = 17.21; p < 0.001$
CSF P-tau, pg/mL	32.3 ± 1.71	40.2 ± 1.94	$F_{1,190} = 9.72; p = 0.002$

Abbreviations: AD = Alzheimer disease; ADAS-Cog = Alzheimer's Disease Assessment Scale, cognitive subscale; AVLT-Sum = sum of the 5 learning trials on the Auditory Rey Verbal Memory Test; CDR-SB = Clinical Dementia Rating scale, sum of boxes score; HC/ICV = hippocampal volume as percent of intracranial volume; HOC = hippocampal occupancy score, ratio of hippocampal volume to hippocampal volume plus volume of the inferior lateral ventricle; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination.

clinical trials incorporating vMRI as outcome measures, have assisted in overcoming these barriers.[18–20] Commercially available, Food and Drug Administration (FDA)–approved medical device image analysis software now exists for fully automated vMRI (NeuroQuant, CorTechs Labs., Inc., La Jolla, CA). Integration of this analysis with clinical practice has been described.[17] Commercial CSF analysis services also exist that can indicate whether CSF biomarkers levels are consistent with AD (e.g., Athena Diagnostics, Worcester, MA).

The purpose of this study is to demonstrate the ability of these clinically available biomarkers, alone or in conjunction with neuropsychological assessment, to predict progression to dementia in patients with MCI.

METHODS

ADNI. Data used in the preparation of this article were obtained from the ADNI database (www.loni.ucla.edu\ADNI). ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations. ADNI's primary goal is to determine the best set of biomarkers for early detection and tracking of AD.

ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations. Subjects have been recruited from over 50 sites across the United States and Canada. ADNI has recruited 230 healthy controls (HCs), 399 patients with amnestic MCI, and 193 with mild AD (for up-to-date information, see www.adni-info.org).

Participants. ADNI eligibility criteria have been described.[9] Briefly, subjects are 55–90 years old, with a study partner able to provide independent evaluation of functioning. HCs have Mini-Mental State Examination (MMSE) scores between 24 and 30, and a Clinical Dementia Rating (CDR) of 0. Subjects with MCI have MMSE scores between 24 and 30, subjective memory complaint, objective memory loss measured by education-adjusted scores on Wechsler Memory Scale Logical Memory II, CDR of 0.5, preserved activities of daily living, and absence of dementia. Subjects with AD have MMSE scores between 20 and 26, CDR of 0.5 or 1.0, and meet National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD.[10] All participants underwent MRI at 1.5 T; approximately half underwent lumbar puncture.

Data collected and processed between August 26, 2005, and October 14, 2010, were analyzed, including 215 HCs and 192 mild AD. The HC group excluded 11 individuals who converted to MCI or AD over the course of the study. MCI participants were limited to 192 subjects with valid baseline Auditory Rey Verbal Learning (AVLT) measures and MRI and CSF data. Table 1 shows demographic and clinical characteristics of the subjects with MCI, separated into those who remained stable over the 3-year follow-up and those who converted to dementia.

Standard protocol approvals, registrations, and patient consents. The research protocol was approved by each local institutional review board and written informed consent was obtained from each participant or participant's guardian.

Procedures. ***MRI acquisition and analyses.*** We downloaded raw baseline DICOM MRI data from the public ADNI Web site (http://www.loni.ucla.edu/ADNI/Data/index.shtml) and performed fully automated volumetric segmentation with the Neuroquant software package, as previously described.[17,21,22] Briefly, images are corrected for gradient nonlinearity and B1 field inhomogeneity, followed by automated segmentation and labeling of 10 subcortical structures, including the hippocampus and the inferior lateral ventricle (ILV), using a probabilistic brain atlas designed specifically to represent the aged population. We visually inspected segmentation results and those with errors (9 out of 822) were discarded. Volumes obtained using NeuroQuant have been validated against computer-assisted manual segmentations, and this software has received FDA approval for clinical use.[21]

We computed a hippocampal occupancy (HOC) score as an estimate of medial temporal lobe atrophy. The HOC was computed as the ratio of hippocampal volume to the sum of the hippocampal and ILV volumes in each hemisphere separately. Right and left HOC scores were averaged then normalized for age and sex.

The HOC is a measure of ex vacuo dilation, indicating expansion of the ILV as a function of brain tissue loss. This measure may aid in differentiation of individuals with congenitally small hippocampi from those with small hippocampi due to a degenerative disorder. We compared the predictive ability of the HOC score with the more commonly used measure of hippocampal volume, corrected for intracranial volume and normalized for age and sex.[23]

CSF acquisition and analysis. CSF sample acquisition and analysis methods have been described.[24] T-tau, p-tau, and β-amyloid$_{1-42}$ ($A\beta_{1-42}$) levels were determined using the

Table 2 Hazard ratios, from Cox proportional hazard models, controlling for age, as a function of risk factor group[a]

Risk factor	Threshold value	No. positive (% positive)	HR (95% CI)
AVLT	33 words	134 (70)	4.1[b] (2.2–7.8)
HOC	−1.02 *z* score	86 (45)	3.9[b] (2.3–6.2)
HC % ICV	−0.96 *z* score	114 (59)	2.3[b] (1.4–3.7)
$A\beta_{1-42}$	192 pg/mL	143 (74)	3.4[b] (1.7–6.9)
t-tau	93 pg/mL	84 (44)	1.8[c] (1.1–2.7)
p-tau	23 pg/mL	137 (71)	2.9[b] (1.6–5.3)
t-tau/$A\beta_{1-42}$ ratio	0.39	134 (70)	4.1[b] (2.1–8.0)
p-tau/$A\beta_{1-42}$ ratio	0.10	150 (78)	3.8[b] (1.8–8.2)
Risk factor combinations		**No. (%)**	**HR (95% CI)**
Atrophy and AVLT			
Negative atrophy, negative AVLT		38 (20)	
Negative atrophy, positive AVLT		68 (35)	9.7[b] (2.31–41.04)
Positive atrophy, negative AVLT		20 (10)	12.3[b] (2.67–57.2)
Positive atrophy, positive AVLT		66 (35)	29.0[b] (7.0–120.03)
tau/$A\beta_{1-42}$ and AVLT			
Negative CSF, negative AVLT		27 (14)	
Negative CSF, positive AVLT		31 (16)	4.4[d] (0.92–20.2)
Positive CSF, negative AVLT		31 (16)	4.5[d] (0.94–21.0)
Positive CSF, positive AVLT		103 (54)	13.8[b] (3.38–57.6)
Atrophy and tau/$A\beta_{1-42}$			
Negative atrophy, negative CSF		38 (20)	
Negative atrophy, positive CSF		68 (35)	4.1[e] (1.4–11.9)
Positive atrophy, negative CSF		20 (10)	4.5[c] (1.3–15.8)
Positive atrophy, positive CSF		66 (35)	13.8[b] (5.0–38.5)

Abbreviations: AVLT = Auditory Rey Verbal Learning Test; CI = confidence interval; HC = healthy control; HOC = hippocampal occupancy; HR = hazard ratio; ICV = intracranial volume.
[a] HRs are expressed relative to the negative risk group for each risk factor alone. No. positive = number of subjects (%) testing positive when each risk factor was examined alone. For the analysis of combinations of risk factors, HRs are expressed relative to the group testing negative on both factors. Number (%) of subjects in each of the 4 categories defined by the combination of each 2 sets of risk factors is shown.
[b] $p \leq 0.001$.
[c] $p < 0.05$.
[d] $p \leq 0.06$.
[e] $p \leq 0.01$.

multiplex xMAP Luminex platform (Luminix Crop, Austin, TX) with the INNO-BIA AlzBio3 kit (Innogenetics, Ghent, Belgium). CSF data are often analyzed commercially using ELISA techniques.[25] Although absolute concentrations differ between Luminix and ELISA methods, measures are highly correlated and provide equivalent diagnostic accuracy for AD.[26,27]

Risk stratification. In separate analyses, we divided MCI participants into positive and negative risk groups using published threshold values for the AVLT learning score, defined as the sum of correctly recalled words on the 5 list-learning trials,[7] and for CSF measures.[24] For atrophy measures, we used linear discriminant analysis to determine the age- and sex-corrected value that maximized accuracy of discriminating AD from HC data. Table 2 shows threshold values for all measures; figure e-1 on the *Neurology*® Web site at www.neurology.org shows receiver operator characteristic curves and table e-1 reports areas under the curve for all measures.

We also stratified MCI participants based on paired combinations of AVLT, vMRI, and CSF risk factors, and on the presence or absence of all 3 risk factors.

Statistical analyses. Using the SPSS software package (version 15.0, SPSS, Inc., Chicago, IL), we performed Cox proportional hazard analyses, correcting for age, to assess risk of converting to AD. We used Kaplan-Meier survival analysis to determine median dementia-free survival time. Time to event is the difference (in months) between the baseline visit and the halfway point between the last visit at which the patient was diagnosed with MCI and the first visit at which the patient was diagnosed with AD. Conversion to AD was determined according to NINCDS-ADRDA criteria.

RESULTS Mean conversion-free follow-up time was 29 months (SD 11.6). Figure 1 shows survival curves from the Cox proportional hazards models for the full MCI group and for subjects with MCI separated into negative and positive risk groups based on AVLT, CSF, and atrophy measures. The top portion of table 2 reports the HRs for each risk factor when used alone. Individuals with MCI testing positive for each factor showed significantly greater hazard of converting to AD than those testing negative. Since the discriminative and predictive accuracy of the HOC score exceeded that of the standard hippocampal volume measure, we used the HOC score as the atrophy biomarker in combined risk factor analyses. Similarly, since the T-tau/$A\beta_{1-42}$ ratio showed the best discriminative and predictive ability of all CSF measures, combined risk factor analyses used this ratio as the CSF biomarker. Since $A\beta$ biomarkers are of great interest as early indicators of AD pathology[28–30] we evaluated combinations of CSF $A\beta_{1-42}$ with AVLT and atrophy risk and present the results in figure e-2 and table e-2.

Figure 2 shows survival curves for risk groups defined by the combination of risk factors. Combining information from any 2 risk categories dramatically improved risk discrimination (table 2, lower portion). The combination of AVLT and medial temporal atrophy provided the best predictive ability. Individuals testing negative for severe learning impairment and for atrophy were at very low risk of converting to AD: 95% of these patients remained stable through the 3-year follow-up period. In contrast, individuals with both atrophy and learning impairment were at very high risk of converting to AD: only 15% were free of dementia at 3 years. Almost

Figure 1 Survival curves according to risk category



Survival curves for the full mild cognitive impairment (MCI) cohort, and for negative and positive risk groups defined according to learning performance (Auditory Rey Verbal Learning Test [AVLT]), CSF T-tau, $A\beta_{1-42}$, and the tau/$A\beta_{1-42}$ ratio, as well as for medial temporal atrophy determined from the hippocampal occupancy score (HOC). Cox proportional hazard models controlled for age. The x-axis shows months to conversion to AD; the y-axis shows proportion of subjects who have not converted to Alzheimer disease. High risk is shown in red, low risk in blue.

half the sample was discordant for these 2 measures. These individuals were also at elevated risk of conversion, although risk was not as high as when both factors were present: approximately 50% of these patients remained free of dementia at 3 years.

We also created groups based on concordant negative (n = 18) or positive risk for all 3 factors (n = 55). None of the individuals in the concordant negative-risk group converted to AD whereas more than 85% of those who tested positive on all 3 mea-

Figure 2 Survival curves as a function of risk factor combinations



Survival curves are shown for patients with mild cognitive impairment stratified according to the combination of learning (Auditory Rey Verbal Learning Test [AVLT]) and atrophy (hippocampal occupancy score [HOC]) risk, learning and CSF risk, atrophy and CSF risk, and for individuals concordant on risk for all 3 measures. Cox proportional hazard model controlled for age. Green lines show those testing negative on all measures in the analysis, red lines show those testing positive on all measures. Blue and purple lines show survival for those with discordant risk factors.

sures had converted to AD within 3 years (figure 2). Since there were no converters in the low-risk group, we could not compute a HR.

Figure 3 shows median survival times for the high-risk group for each risk category. Median survival time was significantly shorter (as determined by the nonoverlapping error bars) for those at risk due to atrophy, alone (15.5 months) or in combination with other factors (15.0 months), than for those at risk from any other measure or combination of measures (range 20.5–28.5 months).

To determine whether random-censoring differed by risk group, we examined censoring as a function of AVLT risk. A total of 43 cases were random-censored (i.e., they did not complete all study visits and were classified as MCI at the last available visit). Most of these patients were at high risk (n = 30; $\chi^2 = 5.13$; $p = 0.024$). Length of follow-up did not significantly differ: 15.3 ± 9.2 vs 20.5 ± 10.6 months for the high- vs low-risk groups ($F_{1,41} = 2.6$; $p = 0.11$).

DISCUSSION Clinically available behavioral, CSF, and vMRI biomarkers each predict risk of conversion to AD in MCI, but combinations of these measures substantially improve prediction. We found that severity of learning impairment assessed with the AVLT predicted increased risk of conversion to AD, with a HR similar to that reported in a study of a smaller subset of ADNI participants.[7] Abnormal CSF biomarkers levels were also predictive of conversion to AD, with HRs equivalent to those in a prior study of all ADNI MCI participants with CSF data.[8] Importantly, we also found that medial temporal atrophy quantified with commercially available vMRI analysis software predicted conversion to AD with larger HRs than those reported in

Figure 3 Median survival times for those testing positive on each risk factor or combination of risk factors



Median survival time (in months) reflects the last time at which 50% of the subjects in the group retained the MCI diagnosis. AVLT = Auditory Rey Verbal Learning Test.

studies of ADNI data that used research vMRI analysis tools.[5,7,10]

Because diagnosis of AD and MCI are based, in part, on severity of cognitive dysfunction, use of neuropsychological test performance as a predictor is circular. However, MCI is associated with a range of severity. The more severe the cognitive impairment, the more likely the patient is to decline to dementia. While we used the AVLT in our models as a "predictor," it might be better conceptualized as a measure of severity within the MCI category.

Recently updated guidelines for diagnosis of MCI in research studies incorporate vMRI and CSF biomarkers.[30] The goal of biomarker characterization is to increase certainty that a person diagnosed with MCI has or does not have underlying AD pathophysiology. Besides providing etiologic specificity, studies such as ours and many others show that patients with MCI with AD biomarkers are more likely to decline to dementia within a few years than patients without AD biomarkers. Thus, assessment of etiology also provides important prognostic information.

Our results showed that combining AVLT performance with CSF or vMRI biomarkers substantially improved risk prediction, consistent with prior findings demonstrating the complementary nature of behavioral, CSF, and MRI measures.[5,7,9,10,12,31] We found that the combination of impaired learning ability and medial temporal atrophy was associated with the greatest risk of developing dementia. Further, we found that the presence of medial temporal lobe atrophy, when considered alone or in combination with other factors, was associated with the most rapid rate of conversion, with median survival times of approximately 15 months. Individuals at risk due to severity of learning impairment or abnormal CSF biomarkers showed a less rapid course of decline, with median survival times of 20 to 28 months. This is consistent with the previously suggested dynamic cascade of AD pathology, in which atrophy is the pathologic event that immediately precedes, and underlies, functional decline to dementia.[32]

In contrast to the immediacy of medial temporal atrophy to functional decline, much research suggests that Aβ pathology develops years or decades prior to cognitive symptoms.[29,32–34] Aβ pathology is observed in a substantial number (20%–40%) of cognitively healthy elderly individuals[35] (including 38% of ADNI's healthy controls[24]). It is not clear whether these individuals will eventually develop AD. Evidence suggests that some healthy elderly who test positive for Aβ pathology are at risk for cognitive decline.[29,33,36] When Aβ pathology occurs with memory impairment, however, it is associated with significantly higher risk of converting to AD.[10]

Using evidence of Aβ pathology from CSF measures or Pittsburgh compound B amyloid imaging, a recent study reported equivalent HRs for hippocampal atrophy and Aβ biomarkers when subjects with MCI were separated into those with highest and lowest quartile scores.[10] Further, the study reported that patients with MCI testing positive for Aβ pathology were more likely to convert to AD when hippocampal atrophy was present. The current results are consistent with this, but also show that absence of Aβ

pathology in MCI does not imply a benign clinical course. Individuals in the current study with normal $A\beta_{1-42}$ levels but with medial temporal atrophy (figure e-2) showed almost as high risk of converting to dementia as individuals testing positive for both factors (HR 9.8 vs 14.3; see table e-2). Although caution in interpretation is warranted by the few subjects in this subgroup (n = 14), these results might reflect a lack of sensitivity of CSF $A\beta_{1-42}$ to the oligomeric form of $A\beta$, which has been shown to be synaptotoxic.[37] Alternatively, dementia in these patients may be due to causes other than AD. In any case, these results suggest that patients with medial temporal atrophy require close monitoring of functional status over time, regardless of $A\beta$ status.

Presently, CSF measures are not routinely included in clinical evaluation of suspected AD in the United States, although such measures are routinely used in some European countries. Multisite studies have demonstrated significant variability in CSF measures across laboratories, but have also shown that uniform collection, handling, and analysis methods can reduce variability, enabling meaningful clinical interpretation.[4] Further efforts are underway to allow standardization of measures across international centers.[4]

Structural MRIs may be included in the clinical workup, but typical scanning protocols are not conducive to automated volumetry. However, obtaining suitable scans in clinical practice requires minor, easily implemented changes in the imaging protocol: ADNI-compatible 3-dimensional T1-weighted scans take about 7 minutes to acquire. These scans can then be analyzed, using fully automated procedures followed by qualitative review by an imaging expert or trained technician, to obtain volumes for various brain structures implicated in AD, including hippocampus, ventricles, and whole brain volume, relative to sex- and age-matched normative values.[17,21,38]

The improved predictive prognostic information available from combined use of these measures argues strongly for their inclusion in the clinical investigation of suspected AD. Evidence of negative CSF or negative atrophy risk factors, with relatively intact learning ability, may allow a clinician to offer reassurance to patients with MCI that the likelihood of progressing to AD in the near term is small. Approximately 95% of patients with MCI in this study who tested negative for learning and atrophy risk factors and 92% of those testing negative for learning and CSF risk factors remained dementia-free after 3 years. When all 3 risk factors were negative, none of the individuals with MCI converted to AD. However, the very few subjects in this group warrants caution in generalizing these findings beyond the present study.

In contrast, a more aggressive course of treatment and care planning would be called for when either atrophy or CSF risk factors are present. When both occur in the presence of learning impairment, risk of AD within 3 years is close to 90%. Although no disease-altering treatments are yet available for AD, information on increased risk of imminent clinical decline would enable clinicians to better anticipate potential problems in management of other chronic conditions and would enable patients and their families to better plan for the future. If disease-modifying therapies become available, accurate early diagnosis will be essential for risk:benefit assessments in treatment decisions since these therapies may be associated with risk of significant adverse effects.[39] Accurate, early detection of prodromal AD would then enable patients to be treated at the earliest possible stage to preserve cognitive abilities without exposing individuals unlikely to progress to AD to undue risk.[40]

One limitation of this study is the loss of some subjects with MCI to follow-up, which may have resulted in a conservative bias in estimate of conversion rates: individuals who dropped out of the study were more likely to fall into the high-risk group based on the learning measure than into the low-risk group, and several may have converted to AD within the timeframe of the follow-up without our knowledge. Other important limitations include lack of histopathologic verification of AD and the highly selected amnestic MCI population. MCI participants within ADNI were carefully selected to include individuals with documented memory impairment and to exclude those whose impairment could arise from other potential causes. Thus the MCI population studied here is not representative of the general clinical population. There is a strong need to gain more experience with currently available clinical tools for aiding in the prediction of AD in the clinical setting, so that if disease-modifying treatments become available, these techniques will have been validated on typical clinical populations and be ready for routine use.

AUTHOR CONTRIBUTIONS

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI or provided data but did not participate in analysis or writing of this report. Dr. Heister: statistical analyses, data interpretation, drafted manuscript. Dr. Brewer: data interpretation, manuscript revision for intellectual content. Dr. Magda: morphometric analysis, manuscript revision for intellectual content. Dr. Blennow: data interpretation, manuscript revision for intellectual content. Dr. McEvoy: study conception and design, statistical analyses, data interpretation, manuscript revision for intellectual content.

COINVESTIGATORS

ADNI coinvestigators: William Jagust, MD (UC Berkeley, Executive Committee, Core PI for PET Core); John Trojanowki, MD, PhD (University of Pennsylvania, Executive Committee, Core PI for Biomarkers Core); Arthur W. Toga, PhD (UCLA, Executive Committee, Core PI for Informatics Core); Laurel Beckett, PhD (UC Davis, Executive Committee, Core PI of Biostatistics Core); Robert C. Green, MD, MPH (Boston University, Chair of Data and Publication Committee); Anthony Gamst, PhD (UC San Diego, Executive Committee, Clinical Informatics and Operations, ADCS Statistics and Informatics Lead); Andrew J. Saykin, PsyD (Indiana University, Executive Committee); John Morris, MD (Washington University, Executive Committee, Neuropathology Core); William Z. Potter, MD, PhD (MERCK Research Laboratories, Chair of Industry Scientific Advisory Board); Tom Montine, MD, PhD (University of Washington, Chair of Resource Allocation Review Committee); Ronald G. Thomas, PhD (UC San Diego, Clinical Informatics and Operations); Michael Donohue, PhD (UC San Diego, Clinical Informatics and Operations); Sarah Walter, MSc (UC San Diego, Clinical Informatics and Operations); Anders Dale, PhD (UC San Diego, Core Leader); Matthew Bernstein, PhD (Mayo Clinic, Core Leader); Joel Felmlee, PhD (Mayo Clinic, Core Leader); Nick Fox, MD (University of London, Core Leader); Paul Thompson, PhD (UCLA School of Medicine, Core Leader); Gene Alexander, PhD (Banner Alzheimer's Institute, Core Leader); Charles DeCarli, MD (UC Davis, Core Leader); Dan Bandy, MS, CNMT (Banner Alzheimer's Institute, PET Core); Robert A. Koeppe, PhD (University of Michigan, PET Core); Norm Foster, MD (University of Utah, PET Core); Eric M. Reiman, MD (Banner Alzheimer's Institute, PET Core); Kewei Chen, PhD (Banner Alzheimer's Institute, PET Core); Chet Mathis, MD (University of Pittsburgh, PET Core); Nigel J. Cairns, PhD, MRCPath (Washington University, Neuropathology Core); Lisa Taylor-Reinwald, BA, HTL (Washington University, Neuropathology Core); Les Shaw, PhD (University of Pennsylvania, Biomarkers Core); Virginia M.-Y. Lee, PhD, MBA (University of Pennsylvania, Biomarkers Core); Magdalena Korecka, PhD (University of Pennsylvania, Biomarkers Core); Karen Crawford (UCLA, Informatics Core); Scott Neu, PhD (UCLA, Informatics Core); Danielle Harvey, PhD (UC Davis, Biostatics Core); John Kornak, PhD (UC Davis, Biostatics Core); Andrew J. Saykin, PsyD (Indiana University, Genetics Core); Tatiana M. Foroud, PhD (Indiana University, Genetics Core); Steven Potkin, MD (UC Irvine, Genetics Core); Li Shen, PhD (Indiana University, Genetics Core); Zaven Kachaturian, PhD (Khachaturian, Radebaugh & Associates [KRA], Inc, Project Development); Alzheimer's Association's Ronald and Nancy Reagan's Research Institute (Project Development); Richard Frank, MD, PhD (General Electric, Project Development); Peter J. Snyder, PhD (University of Connecticut, Project Development); Susan Molchan, PhD (National Institute on Aging/NIH); Jeffrey Kaye, MD (Oregon Health and Science University, Site Investigator); Sara Dolen, BS (Oregon Health and Science University, Site Investigator); Joseph Quinn, MD (Oregon Health and Science University, Site Investigator); Lon Schneider, MD (University of Southern California, Site Investigator); Sonia Pawluczyk, MD (University of Southern California, Site Investigator); Bryan M. Spann, DO, PhD (University of Southern California, Site Investigator); James Brewer, MD, PhD (University of California San Diego, Site Investigator); Helen Vanderswag, RN (University of California San Diego, Site Investigator); Judith L. Heidebrink, MD, MS (University of Michigan, Site Investigator); Joanne L. Lord, LPN, BA, CCRC (University of Michigan, Site Investigator); Kris Johnson, RN (Mayo Clinic, Site Investigator); Rachelle S. Doody, MD, PhD (Baylor, Site Investigator); Javier Villanueva-Meyer, MD (Baylor, Site Investigator); Munir Chowdhury, MS (Baylor, Site Investigator); Yaakov Stern, PhD (Columbia, Site Investigator); Lawrence S. Honig, MD, PhD (Columbia, Site Investigator); Karen L. Bell, MD (Columbia, Site Investigator); Mark A. Mintun, MD (Washington University, Site Investigator); Stacy Schneider, APRN, BC, GNP (Washington University, Site Investigator); Daniel Marson, JD, PhD (University of Alabama–Birmingham, Site Investigator); Randall Griffith, PhD, ABPP (University of Alabama–Birmingham, Site Investigator); David Clark, MD (University of Alabama–Birmingham, Site Investigator); Hillel Grossman, MD (Mount Sinai School of Medicine, Site Investigator); Cheuk Tang, PhD (Mount Sinai School of Medicine, Site Investigator); George Marzloff, BS (Mount Sinai School of Medicine, Site Investigator); Leyla deToledo-Morrell, PhD (Rush University Medical Center, Site Investigator); Raj C. Shah, MD (Rush University Medical Center, Site Investigator); Ranjan Duara, MD (Wein Center, Site Investigator); Daniel Varon, MD (Wein Center, Site Investigator); Peggy Roberts, CNA (Wein Center, Site Investigator); Marilyn S. Albert, PhD (Johns Hopkins, Site Investigator); Nicholas Kozauer, MD (Johns Hopkins, Site Investigator); Maria Zerrate, MD (Johns Hopkins, Site Investigator); Henry Rusinek, PhD (NYU, Site Investigator); Mony J. de Leon, EdD (NYU, Site Investigator); Susan M. De Santi, PhD (NYU, Site Investigator); P. Murali Doraiswamy, MD (Duke, Site Investigator); Jeffrey R. Petrella, MD (Duke, Site Investigator); Marilyn Aiello, BS (Duke, Site Investigator); Steve Arnold, MD (University of Pennsylvania, Site Investigator); Jason H. Karlawish, MD (University of Pennsylvania, Site Investigator); David Wolk, MD (University of Pennsylvania, Site Investigator); Charles D. Smith, MD (University of Kentucky, Site Investigator); Curtis A. Given II, MD (University of Kentucky, Site Investigator); Peter Hardy, PhD (University of Pennsylvania, Site Investigator); Oscar L. Lopez, MD (University of Pittsburgh, Site Investigator); MaryAnn Oakley, MA (University of Pittsburgh, Site Investigator); Donna M. Simpson, CRNP, MPH (University of Pittsburgh, Site Investigator); M. Saleem Ismail, MD (University of Rochester, Site Investigator); Connie Brand, RN (University of Rochester, Site Investigator); Jennifer Richard, BA (University of Rochester, Site Investigator); Ruth A. Mulnard, DNSc, RN, FAAN (UC Irvine, Site Investigator); Gaby Thai, MD (UC Irvine, Site Investigator); Catherine McAdams-Ortiz, MSN, RN, A/GNP (UC Irvine, Site Investigator); Ramon Diaz-Arrastia, MD, PhD (UT Southwestern, Site Investigator); Kristen Martin-Cook, MA (UT Southwestern, Site Investigator); Michael DeVous, PhD (UT Southwestern, Site Investigator); Allan I. Levey, MD, PhD (Emory, Site Investigator); James J. Lah, MD, PhD (Emory, Site Investigator); Janet S. Cellar, RN, MSN (Emory, Site Investigator); Jeffrey M. Burns, MD (University of Kansas, Site Investigator); Heather S. Anderson, MD (University of Kansas, Site Investigator); Mary M. Laubinger, MPA, BSN (University of Kansas, Site Investigator); Liana Apostolova, MD (UCLA, Site Investigator); Daniel H.S. Silverman, MD, PhD (UCLA, Site Investigator); Po H. Lu, PsyD (UCLA, Site Investigator); Neill R. Graff-Radford, MBBCH, FRCP (Mayo, Site Investigator); Francine Parfitt, MSH, CCRC (Mayo, Site Investigator); Heather Johnson, MLS, CCRP (Mayo, Site Investigator); Martin Farlow, MD (Indiana University, Site Investigator); Scott Herring, RN (Indiana University, Site Investigator); Ann M. Hake, MD (Indiana University, Site Investigator); Christopher H. van Dyck, MD (Yale, Site Investigator); Martha G. MacAvoy, PhD (Yale, Site Investigator); Amanda L. Benincasa, BA (Yale, Site Investigator); Howard Chertkow, MD (McGill, Site Investigator); Howard Bergman, MD (McGill, Site Investigator); Chris Hosein, MEd (McGill, Site Investigator); Sandra Black, MD, FRCP (Sunnybrook Health Sciences Ontario, Site Investigator); Bojana Stefanovic, MD (Sunnybrook Health Sciences Ontario, Site Investigator); Curtis Caldwell, PhD (Sunnybrook Health Sciences Ontario, Site Investigator); Ging-Yuek Robin Hsiung, MD, MHSc, FRCPC (UBC Clinic for Alzheimer's Disease, Site Investigator); Howard Feldman, MD, FRCP (UBC Clinic for Alzheimer's Disease, Site Investigator); Michele Assaly, MA (UBC Clinic for Alzheimer's Disease, Site Investigator); Andrew Kertesz, MD (Cognitive Neurology St. Josephs, Site Investigator); John Rogers, MD (Cognitive Neurology St. Josephs, Site Investigator); Dick Trost, PhD (Cognitive Neurology St. Josephs, Site Investigator); Charles Bernick, MD (Cleveland Clinic Lou Ruvo Center for Brain Health, Site Investigator); Donna Munic, PhD (Cleveland Clinic Lou Ruvo Center for Brain Health, Site Investigator); Chuang-Kuo Wu, MD, PhD (Northwestern, Site Investigator); Nancy Johnson, PhD (Northwestern, Site Investigator); Marsel Mesulam, MD (Northwestern, Site Investigator); Carl Sadowsky, MD (Palm Beach Neurology, Site Investigator); Walter Martinez, MD (Palm Beach Neurology, Site Investigator); Teresa Villena, MD (Palm Beach Neurology, Site Investigator); Raymond Scott Turner, MD, PhD (Georgetown, Site Investigator); Kathleen Johnson, NP (Georgetown, Site Investigator); Brigid Reynolds, NP (Georgetown, Site Investigator); Reisa A. Sperling, MD (Brigham and Women's, Site Investigator); Dorene M. Rentz, PsyD (Brigham and Women's, Site Investigator); Keith A. Johnson, MD (Brigham and Women's, Site Investigator); Allyson Rosen, PhD (Stanford, Site Investigator); Jared Tinklenberg, MD

(Stanford, Site Investigator); Wes Ashford, MD, PhD (Stanford, Site Investigator); Marwan Sabbagh, MD, FAAN, CCRI (Sun Health Research Institute, Site Investigator); Donald Connor, PhD, PhD (Sun Health Research Institute, Site Investigator); Sandra Jacobson, MD (Sun Health Research Institute, Site Investigator); Ronald Killiany, PhD (Boston University, Site Investigator); Alexander Norbash, MD (Boston University, Site Investigator); Anil Nair, MD (Boston University, Site Investigator); Thomas O. Obisesan, MD, MPH (Howard University, Site Investigator); Annapurni Jayam-Trouth, MD (Howard University, Site Investigator); Paul Wang, PhD (Howard University, Site Investigator); Alan Lerner, MD (Case Western University, Site Investigator); Leon Hudson, MPH (Case Western University, Site Investigator); Paula Ogrocki, PhD (Case Western University, Site Investigator); Charles DeCarli, MD (UC Davis, Site Investigator); Evan Fletcher, PhD (UC Davis, Site Investigator); Owen Carmichael, PhD (UC Davis, Site Investigator); Smita Kittur, MD (Neurological Care of CNY, Site Investigator); Michael Borrie, MD (Parkwood Hospital, Site Investigator); T.-Y. Lee, PhD (Parkwood Hospital, Site Investigator); Rob Bartha, PhD (Parkwood Hospital, Site Investigator); Sterling Johnson, PhD (University of Wisconsin, Site Investigator); Sanjay Asthana, MD (University of Wisconsin, Site Investigator); Cynthia M. Carlsson, MD (University of Wisconsin, Site Investigator); Steven G. Potkin, MD (UC Irvine, Site Investigator); Adrian Preda, MD (UC Irvine, Site Investigator); Dana Nguyen, PhD (UC Irvine, Site Investigator); Pierre Tariot, MD (Banner Alzheimer's Institute, Site Investigator); Adam Fleisher, MD (Banner Alzheimer's Institute, Site Investigator); Stephanie Reeder, BA (Banner Alzheimer's Institute, Site Investigator); Vernice Bates, MD (Dent Neurologic Institute, Site Investigator); Horacio Capote, MD (Dent Neurologic Institute, Site Investigator); Michelle Rainka, PhD (Dent Neurologic Institute, Site Investigator); Barry A. Hendin, MD (Dent Neurologic Institute, Site Investigator); Douglas W. Scharre, MD (Ohio State, Site Investigator); Maria Kataki, MD, PhD (Ohio State, Site Investigator); Earl A. Zimmerman, MD (Albany, Site Investigator); Dzintra Celmins, MD (Albany, Site Investigator); Alice D. Brown, FNP (Albany, Site Investigator); Godfrey Pearlson, MD (Hartford Hospital, Site Investigator); Karen Blank, MD (Hartford Hospital, Site Investigator); Karen Anderson, RN (Hartford Hospital, Site Investigator); Andrew J. Saykin, PsyD (Dartmouth, Site Investigator); Robert B. Santulli, MD (Dartmouth, Site Investigator); Jessica Englert, PhD (Dartmouth, Site Investigator); Jeff D. Williamson, MD, MHS (Wake Forest, Site Investigator); Kaycee M. Sink, MD, MS (Wake Forest, Site Investigator); Franklin Watkins, MD (Wake Forest, Site Investigator); Brian R. Ott, MD (Rhode Island Hospital, Site Investigator); Edward Stopa, MD (Rhode Island Hospital, Site Investigator); Geoffrey Tremont, PhD (Rhode Island Hospital, Site Investigator); Stephen Salloway, MD, MS (Butler Hospital, Site Investigator); Paul Malloy, PhD (Butler Hospital, Site Investigator); Stephen Correia, PhD (Butler Hospital, Site Investigator); Howard J. Rosen, MD (UC San Francisco, Site Investigator); Bruce L. Miller, MD (UC San Francisco, Site Investigator); Jacobo Mintzer, MD, MBA (Medical University South Carolina, Site Investigator); Crystal Flynn Longmire, PhD (Medical University South Carolina, Site Investigator); Kenneth Spicer, MD, PhD (Medical University South Carolina, Site Investigator).

ACKNOWLEDGMENT

The authors thank Anders Dale and Rahul Desikan for discussions.

STUDY FUNDING

Supported by the NIH (NIA K01AG029218; NINDS K02NS067427). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). D.H. was supported by Scripps Mercy Hospital, San Diego, CA. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from the following: Abbott, AstraZeneca, Bayer Schering Pharma, Bristol-Myers Squibb, Eisai Inc., Elan Corporation, Genentech, Inc., GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis, Pfizer Inc, Roche, Schering-Plough Corp., Synarc, Inc., and Wyeth, as well as nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. None of the study sponsors had any role in the design and conduct of the current study, or in data analysis, interpretation, preparation, review, or approval of the manuscript.

DISCLOSURE

This article evaluates MRI analysis software NeuroQuant, developed by CorTechs Labs, Inc., La Jolla, CA. Three authors (Dr. McEvoy, Dr. Brewer, Dr. Magda) have a financial interest in this company as described in their individual disclosures below. Dr. Heister received research support from the NIH/NINDS. Dr. Brewer has served on a scientific advisory board for Elan Corporation; serves as Special Issue Editor for the *International Journal of Alzheimer's Disease*; estimates that 3% of his clinical effort is spent conducting quantitative segmental volume reporting and assessment; receives research support from Janssen Alzheimer Immunotherapy, General Electric Medical Foundation, the NIH (NINDS, NIA); and holds stock/stock options in CorTechs Labs, Inc. Dr. Magda is the director of Science and Engineering at CorTechs Labs, Inc. Dr. Blennow has served on scientific advisory boards for Pfizer Inc, Innogenetics, Octapharma AG, and Baxter International Inc.; has received speaker honoraria from Janssen Immunotherapy; serves on the editorial board of *Neurodegenerative Diseases*; serves as a consultant for AstraZeneca and Bristol-Myers Squibb; and has received research support from Bristol-Myers Squibb, The Research Council, Sweden, LUA/ALF project, Västra Götalandsregionen, Sweden, The Swedish Alzheimer Foundation, Stiftelsen för Gamla Tjänarinnor, The King Gustaf V and Queen Victoria Foundation, The Swedish Brain Power project, and The Swedish Council for Working Life and Social Research. Dr. McEvoy receives research support from the NIH (NIA, NINDS) and the Alzheimer's Association and her spouse is president of and holds stock and stock options in CorTechs Labs, Inc.

Received February 11, 2011. Accepted in final form June 27, 2011.

REFERENCES

1. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68:828–836.
2. McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009;251:195–205.
3. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385–393.
4. Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis 2010;2010:610–613.
5. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294–301.
6. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949–956.
7. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230–238.

8. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011;121:597–609.
9. Bouwman FH, Schoonenboom SN, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070–1074.
10. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336–3348.
11. Eckerstrom C, Andreasson U, Olsson E, et al. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement Geriatr Cogn Disord 2010;29:294–300.
12. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging Epub 2010 Dec 13.
13. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.
14. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–144.
15. Zetterberg H, Mattsson N, Blennow K. Cerebrospinal fluid analysis should be considered in patients with cognitive problems. Int J Alzheimers Dis 2010;163065.
16. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143–1153.
17. Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav Neurol 2009;21:21–28.
18. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–691.
19. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009;13:550–557.
20. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–2070.
21. Brewer JB, Magda S, Airriess C, Smith ME. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol 2009;30:578–580.
22. Kovacevic S, Rafii MS, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2009;23:139–145.
23. Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992;42:183–188.
24. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403–413.
25. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–613.
26. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–345.
27. Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 2007;53:859–865.
28. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117–128.
29. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469–1475.
30. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement 2011;7:270–279.
31. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 2010;30:2088–2101.
32. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–128.
33. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476–1481.
34. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7: 280–292.
35. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371–380.
36. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343–349.
37. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009;106:4012–4017.
38. McEvoy LK, Brewer JB. Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother 2010;10:1675–1688.
39. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24:198–203.
40. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560–574.